AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03141073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: BID oral administration
Study NCT03141073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID oral administration
Study NCT01737450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT02097043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-7218
Study NCT02097043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02891811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Induction treatment: Cycle 1 day 1+2: 20 mg/m2; days 8,9, 15 and 16: 27 mg/m2; Cycle 2: 27 mg/m2 on days 1,2,8,9,15 and 16; Cycle 3-9: 56 mg/m2 on days 1, 8 and 15; IV duration: 30-60 minutes; Maintenance treatment with carfilzomib (last tolerated dose on day 1 and 15 (± 7 days) of each cycle)
Study NCT02891811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: Induction treatment: Cycle 1 day 1+2: 20 mg/m2; days 8,9, 15 and 16: 27 mg/m2; Cycle 2: 27 mg/m2 on days 1,2,8,9,15 and 16; Cycle 3-9: 56 mg/m2 on days 1, 8 and 15; IV duration: 30-60 minutes; Maintenance treatment with carfilzomib (last tolerated dose on day 1 and 15 (± 7 days) of each cycle)
Study NCT00833625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT (FDG PET/CT)
Description: PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).
Study NCT00833625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomarker Testings
Description: Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis.
Study NCT00828828 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influenza Vaccine
Description: One 0.5 ml dose of influenza vaccine injected intramuscular.
Study NCT02891811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100mg orally on days 1-28 in patients \<75 years of age at Cycle 1; 50mg p.o. on days 1-28 in patients ≥ 75 years of age at Cycle 1
Study NCT02891811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: 25mg p.o. on days 1-21 of each cycle
Study NCT02891811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg p.o. on days 1, 8, 15,22 (± 1 day ) in patients \<75 years of age at Cycle 1; 20mg p.o. on days 1, 8, 15, 22 (± 1 day) in patients ≥ 75 years of age at Cycle 1, given 4 hours-30 min prior to carfilzomib
Study NCT02891811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40mg p.o. on days 1, 8, 15,22 (± 1 day ) in patients \<75 years of age at Cycle 1; 20mg p.o. on days 1, 8, 15, 22 (± 1 day) in patients ≥ 75 years of age at Cycle 1, given 4 hours-30 min prior to carfilzomib
Study NCT00812747 — intervention group
Intervention type: OTHER
Intervention: observation
Study NCT00736879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, Once Daily, Up to 24 weeks
Study NCT00736879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, Once Daily, Up to 24 weeks
Study NCT02010827 — intervention group
Intervention type: BIOLOGICAL
Intervention: isoglycemic intravenous glucose infusion and Glucagon infusion, day C
Description: Infusion of 0.8ng/kg/min glucagon from time 0-25min
Study NCT02010827 — intervention group
Intervention type: BIOLOGICAL
Intervention: Oral glucose tolerance test, day A
Study NCT01379937 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™ Junior
Description: Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
Study NCT02010827 — intervention group
Intervention type: BIOLOGICAL
Intervention: intravenous iv glucose infusion, day B
Study NCT01121731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon α-5
Description: 3 MIU or safe dose used three times a week (TIW) in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
Study NCT01121731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-α5 plus Interferon-α 2b
Description: Interferon-α5 plus Interferon-α 2b. 1.5 MIU each, or safe dose used TIW in alternate days in combined therapy. 29 days of treatment. Subcutaneous injection.
Study NCT01121731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon α-2b (INTRON® A)
Description: 3 million IU TIW in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
Study NCT00931736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
Study NCT00931736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and \< 50 kg, otherwise 300 mg for those weighing \< 36 kg. Total duration of treatment is for 4 months.
Study NCT01698112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed High Dose
Description: 26 gram flaxseed intervention
Study NCT01698112 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed Low Dose
Description: 13 grams flaxseed
Study NCT01669096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' investigational TB vaccine GSK 692342
Description: 2 doses administered intramuscularly according to a 0, 1 month schedule (Day 0 and Day 30), in the deltoid region of the arm
Study NCT03923738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: TCZ will be administered by IV infusion at two dose levels Q4W. The maximum dose of TCZ that will be administered is 800 mg. The dose of TCZ infusion will be calculated on the basis of body weight measured prior to each infusion.
Study NCT01822704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity whole body vibration
Study NCT01822704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity whole body vibration
Study NCT01822704 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Leg exercises
Study NCT01822704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leg exercises
Study NCT00454701 — intervention group
Intervention type: DRUG
Intervention: Alefacept exposure
Description: Observational
Study NCT03583164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorofim
Description: 30mg oral tablets
Study NCT03246620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine oro-dispersible 5Mg Tab
Description: Patient allocated to this arm will be given 5 mg olanzapine oro-dispersible tablet and an encapsulated placebo tablet
Study NCT03246620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol 2Mg encapsulated Tab
Description: Patient allocated to this arm will be given 2 mg encapsulated haloperidol tablet and an oro-dispersible placebo tablet
Study NCT03246620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam 2Mg encapsulated Tab
Description: Patient allocated to this arm will be given 2 mg encapsulated diazepam tablet and an oro-dispersible placebo tablet
Study NCT03433274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tendyne Mitral Valve System
Description: Mitral valve replacement
Study NCT02004392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124
Study NCT02860377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: recorded maternal voice
Description: A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath. ~At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up.
Study NCT03912571 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Based Perfusion Imaging
Description: brain blood flow
Study NCT03912571 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VR-CO2 MRI Scans
Description: reduced vaso reactivity to carbon dioxide
Study NCT02860377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: recorded stranger's voice
Description: A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath.
Study NCT02494362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer gaming hand exercise regimen.
Description: Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for 12 weeks.
Study NCT01727843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: drug and placebo applied topically at end of surgery at hip site.
Study NCT01727843 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: applied topically to surgical site in OR.
Study NCT01404975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (PVB)
Description: We are planning to replace the standard intravenous opioid analgesia with a continuous paravertebral block using local anesthetic after trans-apical aortic valve replacement.~Anesthesia management will be standardized to minimize any impact that anesthetic type may have on neurological outcomes.~Adjuvant supplemental analgesia will be provided to both groups according to the standardized institutional guidelines.
Study NCT01404975 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block (PVB)
Description: We are planning to replace the standard intravenous opioid analgesia with a continuous paravertebral block using local anesthetic after trans-apical aortic valve replacement.~Anesthesia management will be standardized to minimize any impact that anesthetic type may have on neurological outcomes.~Adjuvant supplemental analgesia will be provided to both groups according to the standardized institutional guidelines.
Study NCT01251744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample at study entry, every two months during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
Study NCT01251744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord blood sample
Description: Cord blood sample taken at the time of delivery.
Study NCT02578641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous EBV specific Cytotoxic T cells
Description: The CTL line will be prepared by co-cultivation of the irradiated EBV-LCL with patient PBMC. A proportion of peripheral blood will be used to generate EBV specific CTLs.
Study NCT02578641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination IV gemcitabine and IV carboplatin (AUC2)
Description: 4 cycles for Arm A and 6 cycles for Arm B
Study NCT02578641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combination IV gemcitabine and IV carboplatin (AUC2)
Description: 4 cycles for Arm A and 6 cycles for Arm B
Study NCT03428945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine for oral administration, dosed by weight
Study NCT03428945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet identical to active drug
Study NCT02463630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior Approach Compression Distraction Reduction
Description: Patients was placed in prone position. Via midline skin incision, expose the occipital squama and spinal process, vertebral plate and facet joints of C2. 2 multi-axial screws were inserted into the bilateral C2 or C3 pedicles. The posterior edge of the FM up to the lower boundary of cerebellar tonsil (width, 3mm) was removed. A compression occipital plate (COP) was fixed to the occipital bone. 2 titanium rods connect C2/C3 screws and plate heads bilaterally. The COP screw cap was screwed in, compress the beginning of the pre-bending formed titanium rod downward, driving the odontoid process forward to restore the horizontal dislocation. After restoration of horizontal dislocation is confirmed, applying distraction force between the occipital screw and the C2 pedicle screws, restore the vertical dislocation. tight up the screw cap. Graft bone was harvested from the posterior inferior iliac crest bone and implanted into posterior end of the foramen magnum and posterior lamina of axis.
Study NCT02870439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood drawn
Study NCT02745860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag (adult formulation)
Description: One selexipag film-coated tablet of 200 µg
Study NCT02745860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag (pediatric formulation)
Description: Four selexipag film-coated tablets of 50 µg
Study NCT00779441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem 10mg tablets
Study NCT00779441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem 10mg tablets
Study NCT04325607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of HS followed by NPWTi
Description: The NPWTi that will be used in this study will be the V.A.C. VERAFLO™ Therapy (KCI)
Study NCT02005562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 3 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52, adapted to MPA by AUC on Weeks 2, 6, 12, 26, and 52 to obtain AUC0-12 of 50 milligrams (mg) multiplied by (\*) height (h)/ liter(L).
Study NCT02005562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: 2 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52.
Study NCT02005562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-IL-2R
Description: Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.
Study NCT02005562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti-IL-2R
Description: Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.
Study NCT02005562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.
Study NCT02005562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: 500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.
Study NCT02005562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: 100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52
Study NCT02005562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: 100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52
Study NCT02910596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bethanechol chloride
Description: bethanechol chloride(10) 2 tablets oral tid, ac. Start on3rd - 5th postoperative day
Study NCT02910596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: early bladder training
Description: early bladder training start on 3rd - 5thpostoperative day
Study NCT02910596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early bladder training and bethanechol chloride
Description: bethanechol chloride 2 tablets oral tid, ac and early bladder training start on 3rd - 5th postoperative day
Study NCT02910596 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no early bladder training and no bethanechol chloride
Description: no bethanechol chloride and no early bladder training
Study NCT04325607 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excision of HS followed by NPWT
Description: The NPWT that will be used in this study will be the V.A.C.® Therapy(KCI)
Study NCT02058160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/lixisenatide (HOE901/AVE0010)
Description: Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization.~Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg.
Study NCT02058160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901)
Description: Insulin glargine was self-administered QD by SC injection at approximately the same time every day.~After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).
Study NCT02058160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (Background Drug)
Description: Pharmaceutical form: Tablet; Route of administration: Oral administration
Study NCT02058160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin (Background Drug)
Description: Pharmaceutical form: Tablet; Route of administration: Oral administration
Study NCT02480608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Study NCT02480608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Study NCT02480608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Study NCT02571309 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Asthmatuner
Description: Asthmatuner is an app for self-management of asthma.
Study NCT01138345 — intervention group
Intervention type: GENETIC
Intervention: gene expression analysis
Description: blood samples will be analyzed for the expression of the p16 gene.
Study NCT01138345 — intervention group
Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction
Description: perform reverse transcriptase-polymerase chain reaction on all blood samples.
Study NCT01138345 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: perform laboratory biomarker analysis on all blood samples
Study NCT01138345 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Description: perform medical chart review for all subjects
Study NCT01138345 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: each cohort will be given the same questionnaire
Study NCT03976934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: administration of tamsulosin tablets
Study NCT03976934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: sugar pills
Study NCT02319057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR A
Description: Modified release formulation of ORM-12741
Study NCT01690325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT01690325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT01690325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT01690325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study NCT01251744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saliva swab
Description: Saliva swab taken at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
Study NCT01690325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid